Trial Profile
Clinical study of chimeric antigen receptor gene-modified autologous T cells targeting GPC3 in hepatocellular carcinoma and lung squamous cell carcinoma
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Oct 2016
Price :
$35
*
At a glance
- Drugs GPC3-CAR-T (Primary)
- Indications Liver cancer; Lung cancer; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- 26 Oct 2016 New trial record